Texas Policy Research recommends that lawmakers vote NO on HB 5178. The bill addresses a medically significant use of biomarker testing for organ-transplant patients, but it does so by expanding a state-mandated health insurance benefit. The committee analysis states that the bill would require health benefit plans to provide biomarker testing coverage for enrollees who have received an organ transplant, subject to the same evidence-based conditions already prescribed under current law for other biomarker testing.
The bill grows the scope of government by expanding the state’s authority over private health benefit plan design. It does not create a new agency, office, program, or express rulemaking authority, and the committee analysis specifically states that it does not expressly grant additional rulemaking authority. However, limited-government analysis is not limited to whether a bill creates a new bureaucracy. By adding another statutory coverage requirement to the Insurance Code, the bill increases the state’s role in deciding what private insurance contracts must cover. That represents an expansion in the scope of government regulation over private market arrangements.
The LBB anticipates no significant fiscal implication to the state and no significant fiscal implication to units of local government. It also assumes any revenue implications or costs associated with the bill would be insignificant. On that basis, the bill does not appear to impose a direct, material burden on taxpayers through state or local appropriations. However, the absence of a significant fiscal note does not mean the bill is cost-free. Required insurance benefits can shift costs into private premiums, employer-sponsored coverage, employee contributions, and plan design tradeoffs. Those costs may not appear as a direct state expenditure, but they still affect Texans who purchase or receive regulated health coverage.
The bill increases the regulatory burden on affected health benefit plan issuers by requiring coverage for an additional category of biomarker testing. The bill analysis explains that current law does not explicitly require coverage for biomarker testing for organ transplants and that HB 5178 seeks to add that requirement. This is a substantive regulatory change, not merely a reporting or transparency measure. It limits the ability of insurers, employers, and purchasers to negotiate benefit design based on cost, risk, and consumer preference.
The central objection is structural. The bill may be well-intentioned and medically justified, but it reinforces the precedent that the Legislature should resolve access concerns by adding condition-specific coverage mandates to private insurance law. Over time, that approach can make coverage more expensive, reduce lower-cost plan options, and further separate health care prices from consumer choice and market discipline.
HB 5178 expands government control over private insurance contracts, increases regulatory burden on businesses in the health insurance market, and may indirectly increase costs for employers and covered individuals even though the LBB does not anticipate a significant direct fiscal impact to state or local government.
